Klaas Heyland
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Klaas Heyland.
Journal of Pediatric Gastroenterology and Nutrition | 2012
Klaas Heyland; Michael Friedt; Patrick Buehr; Christian Braegger
Objective: The aim of the study was to investigate whether recurrent abdominal pain (RAP) in Blastocystis hominis–positive children can be treated successfully with trimethoprim-sulfamethoxazole (TMP/SMX). Methods: From October 2004 to December 2008, all of the patients referred to the Division of Gastroenterology and Nutrition of the University Childrens Hospital Zurich because of RAP and detection of B hominis in stool samples as the only pathological finding after a standard workup were offered to participate in the study. Patients were randomly assigned into 2 groups. TMP/SMX or placebo was given for 7 days in a double-blind, placebo-controlled manner. Pain index (PI) was measured with a visual analogue scale. Two weeks after completion of treatment, 3 stool samples were collected and patients were followed clinically. If B hominis was still present, metronidazole was given for 7 days. Results: Forty patients were included; 37 finished the study (TMP/SMX n = 20, placebo n = 17). Mean PI declined from 7.1 to 3.6 for all of the patients, with a decrease from 6.9 to 4.1 in the TMP/SMX and 7.4 to 3.0 in the placebo group, irrespective of detection of B hominis after treatment. There was no statistically significant difference in PI reduction between the 2 groups. Metronidazole treatment led to a further PI decline from 3.7 to 1.9. Eradication rates were 35% (TMP/SMX) and 44% (metronidazole), compared with spontaneous clearance of 29% in the placebo group. Conclusions: There is no advantage for TPM/SMX over placebo in the treatment of RAP in B hominis–positive children.
Journal of Pediatric Gastroenterology and Nutrition | 2017
Thomas Greuter; Fabio Bertoldo; Roman Rechner; Alex Straumann; Luc Biedermann; Jonas Zeitz; Benjamin Misselwitz; Michael Scharl; Gerhard Rogler; Ekaterina Safroneeva; Raja Affendi Raja Ali; Christian Braegger; Klaas Heyland; Pascal Mueller; Andreas Nydegger; Laetitia Marie Petit; Susanne Schibli; Raoul I. Furlano; Johannes Spalinger; Michela Schäppi; Samuel Antonio Zamora; Florian Froehlich; Denise Herzog; Alain Schoepfer; Stephan R. Vavricka
Background: There is a paucity of data on extraintestinal manifestations (EIM) and their treatment in pediatric patients with inflammatory bowel disease (IBD). Methods: Since 2008, the Pediatric Swiss IBD Cohort Study has collected data on the pediatric IBD population in Switzerland. Data on 329 patients were analyzed retrospectively. Results: A total of 55 patients (16.7%) experienced 1–4 EIM (39 Crohn disease, 12 ulcerative colitis, and 4 IBD-unclassified patients). At IBD onset, presence of EIM was more frequent than in the adult population (8.5% vs 5.0%, P = 0.014). EIM were more frequent in Crohn disease when compared to ulcerative colitis/IBD-unclassified (22.5% vs 10.3%, P = 0.003). The most prevalent EIM were peripheral arthritis (26/329, 7.9%) and aphthous stomatitis (24/329, 7.3%). Approximately 27.6% of all EIM appeared before IBD diagnosis. Median time between IBD diagnosis and occurrence of first EIM was 1 month (−37.5–149.0). Thirty-one of the 55 patients (56.4%) were treated with 1 or more anti–tumor necrosis factor (TNF) agents. IBD patients with EIM were more likely to be treated with anti-TNF compared to those without (56.4% vs 35.0%, P = 0.003). Response rates to anti-TNF depended on underlying EIM and were best for peripheral arthritis (61.5%) and uveitis (66.7%). Conclusions: In a cohort of pediatric patients with IBD, EIM were frequently encountered. In up to 30%, EIM appeared before IBD diagnosis. Knowledge of these findings may translate into an increased awareness of underlying IBD, thereby decreasing diagnostic delay. Anti-TNF for the treatment of certain EIM is effective, although a substantial proportion of new EIM may present despite ongoing anti-TNF therapy.
Journal of Crohns & Colitis | 2014
Daniela Rogler; Nicolas Fournier; Valérie Pittet; Patrick Bühr; Klaas Heyland; Michael Friedt; Rebekka Koller; Vanessa Rueger; Denise Herzog; Andreas Nydegger; Michela Schäppi; Susanne Schibli; Johannes Spalinger; Gerhard Rogler; Christian Braegger
BACKGROUND Inflammatory bowel disease (IBD) starting during childhood has been assumed to impair quality of life (QoL) of affected children. As this aspect is crucial for further personality development, the health-related quality of life (HRQOL) was assessed in a Swiss nationwide cohort to obtain detailed information on the fields of impairment. METHODS Data were prospectively acquired from pediatric patients included in the Swiss IBD Cohort Study. IBD activity was evaluated by PCDAI and PUCAI. The age adapted KIDSCREEN questionnaire was evaluated for 110 children with IBD (64 with Crohns disease 46 with ulcerative colitis). Data were analyzed with respect to established reference values of healthy controls. RESULTS In the KIDSCREEN index a moderate impairment was only found for physical wellbeing due to disease activity. In contrast, mental well-being and social support were even better as compared to control values. A subgroup analysis revealed that this observation was restricted to the children in the German speaking part of Switzerland, whereas there was no difference compared to controls in the French part of Switzerland. Furthermore, autonomy and school variables were significantly higher in the IBD patients as compared to controls. CONCLUSIONS The social support for children with IBD is excellent in this cohort. Only physical well-being was impaired due to disease activity, whereas all other KIDSCREEN parameters were better as compared to controls. This indicates that effective coping and support strategies may be able to compensate the burden of disease in pediatric IBD patients.
European Journal of Gastroenterology & Hepatology | 2014
Denise Herzog; Nicolas Fournier; Patrick Buehr; Rebekka Koller; Vanessa Rueger; Klaas Heyland; Andreas Nydegger; Johannes Spalinger; Susanne Schibli; Christian Braegger
Objectives Growth retardation is a frequent complication of paediatric inflammatory bowel disease (IBD). Only a few studies report the final height of these patients, with controversial results. We compared adult height of patients with paediatric IBD with that of patients with adult-onset disease. Methods Height data of 675 women 19–44 years of age and 454 men 23–44 years of age obtained at inclusion in the Swiss IBD cohort study registry were grouped according to the age at diagnosis: (a) prepubertal (men⩽13, women⩽11 years), (b) pubertal (men 13–22, women 11–18 years) and (c) adult (men>22, women>18 years of age), and compared with each other and with healthy controls. Results Male patients with prepubertal onset of Crohn’s disease (CD) had significantly lower final height (mean 172±6 cm, range 161–182) compared with men with pubertal (179±6 cm, 161–192) or adult (178±7 cm, 162–200) age at onset and the general population (178±7 cm, 142–204). Height z-scores standardized against heights of the normal population were significantly lower in all patients with a prepubertal diagnosis of CD (−0.8±0.9) compared with the other patient groups (−0.1±0.8, P<0.001). Prepubertal onset of CD emerged as a risk factor for reduced final height in patients with prepubertal CD. No difference for final height was found between patients with ulcerative or unclassified IBD diagnosed at prepubertal, pubertal or adult age. Conclusion Prepubertal onset of CD is a risk for lower final height, independent of the initial disease location and the necessity for surgical interventions.
Pediatric Gastroenterology, Hepatology & Nutrition | 2014
Denise Herzog; Patrick Buehr; Rebekka Koller; Vanessa Rueger; Klaas Heyland; Andreas Nydegger; Johannes Spalinger; Susanne Schibli; Christian Braegger
Purpose Gender differences in paediatric patients with inflammatory bowel disease (IBD) are frequently reported as a secondary outcome and the results are divergent. To assess gender differences by analysing data collected within the Swiss IBD cohort study database since 2008, related to children with IBD, using the Montreal classification for a systematic approach. Methods Data on gender, age, anthropometrics, disease location at diagnosis, disease behaviour, and therapy of 196 patients, 105 with Crohns disease (CD) and 91 with ulcerative or indeterminate colitis (UC/IC) were retrieved and analysed. Results The crude gender ratio (male : female) of patients with CD diagnosed at <10 years of age was 2.57, the adjusted ratio was 2.42, and in patients with UC/IC it was 0.68 and 0.64 respectively. The non-adjusted gender ratio of patients diagnosed at ≥10 years was 1.58 for CD and 0.88 for UC/IC. Boys with UC/IC diagnosed <10 years of age had a longer diagnostic delay, and in girls diagnosed with UC/IC >10 years a more important use of azathioprine was observed. No other gender difference was found after analysis of age, disease location and behaviour at diagnosis, duration of disease, familial occurrence of IBD, prevalence of extra-intestinal manifestations, complications, and requirement for surgery. Conclusion CD in children <10 years affects predominantly boys with a sex ratio of 2.57; the impact of sex-hormones on the development of CD in pre-pubertal male patients should be investigated.
Archives of Disease in Childhood | 2013
Denise Herzog; Markus A. Landolt; Patrick Buehr; Klaas Heyland; Daniela Rogler; Rebekka Koller; Vanessa Rueger; Valérie Pittet; Andreas Nydegger; Johannes Spalinger; Michela Schäppi; Susanne Schibli; Christian Braegger
Objectives Whether behavioural and emotional maladjustment is more prevalent in children with inflammatory bowel disease (IBD) than in healthy controls remains controversial. The aim of this study was to assess paediatric IBD patients for problems with emotional and behavioural adjustment and to examine associations with clinical and demographic variables. Methods Data from paediatric patients with IBD enrolled in the Swiss IBD Cohort Study and the results of both the parent-rated Strengths and Difficulties Questionnaire (SDQ) and the self-reported Child Depression Inventory (CDI) were analysed. Of the 148 registered patients, 126 had at least one questionnaire completed and were included. Results The mean age of 71 patients with Crohns disease (44 males, 27 females) was 13.4 years, and 12.8 years for the 55 patients with ulcerative or indeterminate colitis. The mean duration of disease was 1.2 and 2.7 years, respectively. The total score of the SDQ was abnormal in 11.4% of cases compared to 10% in the normal population. Abnormal sub-scores were found in 20.2% of subjects for the domain of emotional problems and in 17.1% for problems with peers. The total CDI T score indicated a significantly lower prevalence of clinical depression in IBD patients than in normal youth. No correlation between the total SDQ scores or the CDI T scores and gender, type or duration of IBD, inflammatory markers or disease scores was found. Conclusions The prevalence of problems with behavioural and emotional adjustment among Swiss paediatric IBD patients is low and comparable to that of the normal population.
Quality of Life Research | 2017
Helene Werner; Markus A. Landolt; Patrick Buehr; Rebekka Koller; Andreas Nydegger; Johannes Spalinger; Klaas Heyland; Susanne Schibli; Christian Braegger
PurposeLittle is known about disease-specific health-related quality-of-life (HRQoL) changes over time in paediatric patients with inflammatory bowel disease (IBD), and about their associations with baseline medical characteristics.MethodsIn this study, 153 paediatric patients with IBD from the multicentre prospective Swiss IBD cohort study were included at baseline. Of these, 90 patients were analysed at a 1-year follow-up. Medical data were extracted from hospital records, while HRQoL data were measured using the standardized, self-report disease-specific IMPACT-III questionnaire.ResultsThe IBD diagnosis of the included children was made an average of 2.0 years before their baseline assessment. Over the 1-year follow-up period, a significant increase in overall HRQoL and in the HRQoL domain ‘physical functioning’ was evident. On multivariate analysis, overall HRQoL changes over time were predicted by baseline HRQoL, baseline disease activity, and disease activity changes over time. HRQoL improvements were significantly associated with decreases in physician-assessed disease activity. Children reporting a low baseline HRQoL and children with inactive or mildly-active disease experienced greater improvements.ConclusionsChildren with more severe baseline disease activity had the greatest risk for HRQoL deterioration over the 1-year follow-up period. However, among possible factors that might influence HRQoL changes over time, the child’s medical characteristics explained only a small proportion of their variability in our sample. We, therefore, recommend that researchers and clinicians focus on factors that are not incorporated within the multidimensional HRQoL concept if they seek to gain better insights into factors that influence HRQoL changes over time in children with IBD.
European Journal of Gastroenterology & Hepatology | 2017
Denise Herzog; Nicolas Fournier; Patrick Buehr; Vanessa Rueger; Rebekka Koller; Klaas Heyland; Andreas Nydegger; Christian Braegger
Introduction Intestinal complications in inflammatory bowel disease indicate active inflammation and typically result in the intensification of therapy. Aim To analyse whether the rates of intestinal complications were associated with age at disease onset. Patients and methods Data from 1506 individuals with Crohn’s disease (CD) and 1201 individuals with ulcerative colitis (UC) were obtained from the Swiss inflammatory bowel disease cohort study database, classified into groups on the basis of age at diagnosis (<10, <17, <40 and >40 years of age), and retrospectively analysed. Results In CD patients, the rates of stricturing (29.1–36.2%), abdominal penetrating disease (11.9–18.2%), resectional surgery (17.9–29.8%) and perianal disease (14.7–34.0%) were correlated with disease duration, but not age at diagnosis. However, paediatric-onset CD was associated with higher rates of multiple, rectal and anal strictures and earlier colon surgery. In addition, perianal disease occurred earlier, required earlier surgical intervention, and was more often combined with stricturing and penetrating disease. Finally, anal fissures were more prevalent among younger patients. In UC patients, the rates of progression or extension of disease (0–25.8%) and colectomy (3.0–8.7%) were dependent on disease duration, but not age at disease onset. Paediatric-onset disease was associated with a higher rate of extensive colitis at diagnosis and earlier progression or extension of disease, and nonsurgically treated patients with the youngest ages at onset more frequently required antitumour necrosis factor-&agr; treatments. Conclusion The higher rates of intestinal complications, including those of the small and large bowel and in the anal region, in paediatric-onset CD patients point towards a level of inflammation that is more difficult to control. Similar findings were also evident in UC patients.
Acta Paediatrica | 2015
Helene Werner; Christian Braegger; Patrick Buehr; Rebekka Koller; Andreas Nydegger; Johannes Spalinger; Klaas Heyland; Susanne Schibli; Markus A. Landolt
This study assessed the mental health of parents of children with inflammatory bowel disease (IBD), compared their mental health with age‐matched and gender‐matched references and examined parental and child predictors for mental health problems.
Journal of Crohns & Colitis | 2014
Helene Werner; Markus A. Landolt; Patrick Buehr; Rebekka Koller; Andreas Nydegger; Johannes Spalinger; Klaas Heyland; Susanne Schibli; Christian Braegger